Incorporando los inhibidores de CDK 4/6 a la práctica Clínica habitual

24 / 38

Palbociclib
PALLAS low-high risk 4000
PENELOPE-B Post-neoadjuvant C 1250
Ribociclib
EarLEE-1 high risk 2000
EarLEE-2 intermediate risk 4000
Abemaciclib
MONARCH-E High risk 3580
CDK4/6 inhibitor adjuvant trials